Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

Patient-specific precision medicine approaches are important for future cancer therapies. Here, the authors show that functional drug profiling with Rhabdomyosarcoma cells isolated from PDX and primary patient tumors uncovers patient-specific vulnerabilities.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Gabriele Manzella, Leonie D. Schreck, Willemijn B. Breunis, Jan Molenaar, Hans Merks, Frederic G. Barr, Wenyue Sun, Michaela Römmele, Luduo Zhang, Joelle Tchinda, Quy A. Ngo, Peter Bode, Olivier Delattre, Didier Surdez, Bharat Rekhi, Felix K. Niggli, Beat W. Schäfer, Marco Wachtel
Format: article
Langue:EN
Publié: Nature Portfolio 2020
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/e1a776112ff34407a13275f886ecd3a9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Patient-specific precision medicine approaches are important for future cancer therapies. Here, the authors show that functional drug profiling with Rhabdomyosarcoma cells isolated from PDX and primary patient tumors uncovers patient-specific vulnerabilities.

Documents similaires